Skip to main content

Table 2 Coagulation, platelet function, fibrinolysis and fibrin clot properties

From: Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk

  LOWER glucose group (<4.5 mmol/l) MEDIUM glucose group (4.5-6.0 mmol/l) HIGHER glucose group (>6.0 mmol/l) P-value
Fibrinogen, g/dL 3.06 (2.66-3.48) 3.13 (2.67-3.57) 3.15 (2.64-3.61) 0.98
Peak thrombin, nM 273 (209–380) 225 (201–268)* 236 (196–275)* 0.002
PF4 10.6 (9.1-12.8) 9.5 (8.2-12.0) 10.3 (8.2-12.8) 0.26
sCD40L 4.3 (3.6-4.9) 3.7 (3.1-4.4) 3.8 (3.3-4.8) 0.09
TAFI, % 71.5 (41.6-90.0) 91.0 (84.0-106.0)* 100.0 (92.0-111.0)* <0.0001
PAI-1: Ag 30.6 (25.8-36.1) 32.0 (28.7-36.3) 33.9 (29.4-38.9) 0.23
Plasminogen, % 109 ± 21 108 ± 16 110 ± 14 0.83
Antiplasmin, % 109 (100–118) 109 (96–118) 107 (97–117) 0.61
Ks, cm2x10−9 6.52 ± 0.79 7.29 ± 0.81* 7.06 ± 0.88* 0.0001
t50%, min 10.49 ± 0.97 9.55 ± 0.91* 9.79 ± 1.11* <0.0001
Lag_phase, s 45 (41–50) 44 (41–47.0) 43 (40–45)* 0.019
ΔAbsmax, 405 nm 0.79 (0.76-0.83) 0.81 (0.77-0.86) 0.82 (0.80-0.87)* 0.015
D-Drate mg/L/min 0.069 ± 0.006 0.070 ± 0.005 0.07 ± 0.004 0.47
D-Dmax mg/L 3.90 (3.78-4.22) 3.87 (3.69-4.06) 3.88 (3.62-4.22) 0.30
  1. Values are given as mean ± SD, median (interquartile range). P value was measured using analysis of variance (ANOVA) with post-hoc Bonferroni test or Kruskal-Wallis test with multiple comparisons of mean rank, *p < 0.05 as compared with LOWER glucose group.
  2. Abbreviations: ΔAbsmax, maximum absorbance of fibrin gel at 405 nm determined by using turbidimetry; sCD40L, soluble CD40 ligand; D-Dmax, maximum D-dimer levels in the lysis assay; D-Drate, maximum rate of increase in D-dimer levels in the lysis assay; Ks, permeability coefficient; PAI-1: Ag; plasminogen activator inhibitor-1 antigen; PF4, platelet factor 4; t50%, half-lysis time; TAFI, thrombin-activatable fibrinolysis inhibitor.